Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
GEN Roundup: Multiplex Immunoassays Bring the Array, Not the Disarray
Get Multiplex Immunoassay Advice from GEN's Expert Panel
Solving the Puzzle of Cell Culture Optimization
Assembling a Jigsaw Puzzle Is Not Nearly as Tricky as Building a Stable and Productive Bioprocess
For full access to this article login to GEN Select now.
Peptide Capacity Holding Steady For Now
Improving Delivery Strategies and Enhancing Pharmacokinetic Properties Are Key Concerns
- Industry sources project a continuing 10 to 15% growth in the market for biotherapeutic peptide new chemical entities, and more modest growth of slightly greater than 10% for generic peptides. These projections, however, predate the current global economic downturn and ongoing financial instability, and there is growing concern that ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.